مباشر

BioPharma DiveGSK cuts deal with Sino to broaden reach of hepatitis B drug Endpoints NewsDaiichi eyes almost $15B in oncology sales by 2030 in ADC franchise push Endpoints NewsNew home for Novo's Parkinson's cell therapy; GSK turns to China for hep B drug Clinical OMICsBrain-Controlled Hearing Aid Singles Out Voices in a Crowd BioWorldBiggest gainers and losers for May 4-8, 2026 Endpoints NewsInhibrx says combo therapy shrank more tumors than Merck's Keytruda alone FierceBiotechAmid M&A buzz, Inhibrx's OX40-Keytruda combo shows promise in early look at midphase data FierceBiotechDaiichi Sankyo targets global top 5 oncology rank by 2035, $1.3B efficiency drive in new 5-year plan BioPharma DiveInhibrx delivers ‘differentiated’ cancer drug data; Fractyl starts diabetes gene therapy trial FDA News ReleasesFDA Advances Drug Repurposing to Address Unmet Medical Needs Endpoints NewsBraveheart Bio's Hengrui-licensed cardiac drug scores second clinical win BioPharma DiveBiotech layoffs are easing, but is the worst over?

Labiotech ١١ مايو ٢٠٢٦

Inside CSL’s strategy to simplify a biotech giant

Delve into the Australian biotech giant CSL's strategy to refocus a company built on complex modalities. The post Inside CSL’s strategy to simplify a biotech gi...

Delve into the Australian biotech giant CSL's strategy to refocus a company built on complex modalities. The post Inside CSL’s strategy to simplify a biotech giant appeared first on Labiotech.eu . © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.